Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132812 | 0.87 | HRH3 (0.38) | HRH3APPPTPN11USP2HSD11B1 | |
| SCHEMBL13098866 | 0.86 | HRH3 (0.47) | HRH3PTPN11 | |
| SCHEMBL13098814 | 0.85 | HRH3 (0.39) | HRH3APPPTPN11USP2RAB9A | |
| SCHEMBL6132510 | 0.85 | PDE4D (0.44) | HRH3USP2 | |
| SCHEMBL6134549 | 0.84 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2HRH3APP | |
| SCHEMBL6132560 | 0.84 | PDE4D (0.48) | ALDH1A1KDM4ESMN1; SMN2HRH3USP2 | |
| SCHEMBL6374773 | 0.84 | USP2 (0.43) | HRH3USP2 | |
| SCHEMBL3110248 | 0.84 | HRH3 (0.34) | HRH3APPUSP2 | |
| SCHEMBL6376063 | 0.83 | PDE4D (0.46) | ALDH1A1KDM4ESMN1; SMN2HRH3USP2 | |
| SCHEMBL6134823 | 0.81 | HRH3 (0.38) | SMN1; SMN2HRH3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | claimed |
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | ALDH1A1 1951/4885KDM4E 3543/4885SMN1; SMN2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.